Pacira Update (1-18-13)

 Comments Off on Pacira Update (1-18-13)
Jan 182013
 
Pacira Update (1-18-13)

On a positive note, Pacira pre-released some of their key Q4 financials. The company expects Q4:12 and FY12 revenues to come in above Wall Street consensus estimates, driven by higher net sales of Exparel.  Q4 sales of the drug are targeted at $7.8 million, and total revenues are estimated at $10.5 million, compared to $4.2 […]

Pacira Update (11-20-12)

 Comments Off on Pacira Update (11-20-12)
Nov 202012
 
Pacira Update (11-20-12)

Pacira had good news this morning and the stock is up modestly.  The company announced results from the first IMPROVE study to complete its prospective Phase 4 clinical program. The IMPROVE studies compare the difference in opioid use, total hospital cost and length of stay (LOS) between patients receiving Exparel (bupivacaine liposome injectable suspension) as […]